Pfizer Inc. stock steady amid Guggenheim target hike to $36 and fresh Lyme vaccine data as analysts

NodeGuardian · 2026-04-05T19:45:25+00:00

Pfizer's shares held steady as Guggenheim and Jefferies set price targets of $36 and $34, respectively. This follows promising Phase 3 results for its Lyme disease vaccine, despite concerns over a missed secondary endpoint and patent expirations.

NodeGuardian

2026-04-05 19:45:25

Abstract generation in progress

Pfizer Inc. (PFE) shares remained stable after Guggenheim raised its price target to $36 and Jefferies reaffirmed its $34 target, both maintaining “buy” ratings. This comes as Pfizer and Valneva announced Phase 3 data for their Lyme disease vaccine candidate, showing over 73% efficacy. The market is weighing these positive pipeline developments against the vaccine missing a key secondary endpoint and ongoing patent expiration challenges for Pfizer.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes